A 52-year-old woman from Mumbai undergoes mammography for screening and is found to have a 1.2 cm suspicious mass in the left breast with no palpable lymph nodes on clinical examination. Ultrasound-guided core needle biopsy confirms invasive lobular carcinoma (ILC), grade II, ER/PR positive, HER2 negative. Staging investigations (CT chest/abdomen, bone scan) are negative for distant metastases. Axillary ultrasound shows no suspicious nodes; sentinel lymph node biopsy (SLNB) is planned. Intraoperatively, the sentinel node is identified and removed; frozen section shows no malignancy. What is the most appropriate next step in surgical management?

Explanation

## Clinical Assessment This patient has **T1bN0M0 breast cancer** (1.2 cm tumor, clinically and radiologically node-negative). ### Staging Elements - **Tumor size:** 1.2 cm → T1b (>1 mm, ≤5 mm is T1a; >5 mm, ≤10 mm is T1b; >10 mm, ≤20 mm is T1c) - **Lymph node status:** Clinically negative, radiologically negative, sentinel node negative on frozen section → N0 - **Metastases:** None → M0 - **Overall stage:** IA (T1bN0M0) ## Sentinel Lymph Node Biopsy (SLNB) Interpretation **Key Point:** A negative sentinel node on frozen section in a clinically node-negative patient is sufficient to complete axillary staging. ALND is NOT required. **High-Yield:** In early-stage breast cancer (T1–T2, cN0): - **SLNB is the standard** of care for axillary staging - **Negative SLNB** = axillary dissection can be safely omitted - **Positive SLNB** = ALND is indicated (or observation per ACOSOG Z0011 criteria in selected cases) ### Why ALND Is Not Needed Here 1. **Clinically node-negative** disease 2. **Sentinel node negative** on intraoperative frozen section 3. **No high-risk features** (tumor <5 cm, grade II, ER/PR+) 4. **ACOSOG Z0011 trial** (2011) showed that SLNB alone without ALND is safe in early-stage breast cancer with 1–2 positive sentinel nodes treated with BCT + adjuvant therapy; by extension, node-negative disease requires no ALND ## Next Surgical Step **Proceed with breast-conserving therapy (BCT):** - Wide local excision (WLE) with adequate margins (≥1 mm for invasive carcinoma) - Oncoplastic closure if needed - Plan for whole-breast radiotherapy post-operatively **Clinical Pearl:** Invasive lobular carcinoma (ILC) is not an indication for mastectomy if margins are adequate and patient is suitable for BCT. ILC has similar prognosis to invasive ductal carcinoma when matched for stage and grade. ## Adjuvant Therapy - Whole-breast radiotherapy (standard for BCT) - Hormonal therapy (aromatase inhibitor or tamoxifen) given ER/PR positivity - Chemotherapy generally not indicated for T1N0 disease unless high-grade or other adverse features [cite:Robbins 10e Ch 23; NCCN Breast Cancer Guidelines 2023]